Vamshi Sarangi

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Raches Ella, Krishna Mohan Vadrevu, Harsh Jogdand et al. · The Lancet Infectious Diseases · 2021 · 438 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +12

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Raches Ella, Siddharth Reddy, Harsh Jogdand et al. · The Lancet Infectious Diseases · 2021 · 365 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

Raches Ella, Siddarth Reddy, William C. Blackwelder et al. · The Lancet · 2021 · 362 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +12

Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial

Raches Ella, Siddarth Reddy, William C. Blackwelder et al. · medRxiv · 2021 · 80 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Persisting antibody responses to Vi polysaccharide–tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination

Krishna Mohan Vadrevu, Dugyala Raju, Sandhya Rani et al. · Vaccine · 2021 · 42 citations · Full text

Medicine, Immunology, Pediatrics +17